Cho Fu-Nan, Liu Cheng-Bin
Department of Obstetrics and Gynecology, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ROC.
J Chin Med Assoc. 2008 May;71(5):267-9. doi: 10.1016/S1726-4901(08)70119-9.
Severe maternal thrombocytopenia resulting in hemorrhage is often associated with high mortality. Three cases of severe maternal thrombocytopenia in association with heparin-induced thrombocytopenia (HIT), HELLP syndrome, and systemic lupus erythematosus (SLE) were successfully managed using intravenous immunoglobulin (IVIG). IVIG can reduce the severity of thrombocytopenia and hemolysis, stabilize lupus activity, prevent peripartum hemorrhage, and shorten hospitalization, but it may induce reversible interstitial nephritis and membranous glomerulonephritis. IVIG may be beneficial in the management of severe peripartum maternal thrombocytopenia in association with HIT, HELLP syndrome, and SLE.
严重的孕产妇血小板减少症导致出血往往与高死亡率相关。三例严重的孕产妇血小板减少症分别与肝素诱导的血小板减少症（HIT）、HELLP综合征和系统性红斑狼疮（SLE）相关，通过静脉注射免疫球蛋白（IVIG）成功得到处理。IVIG可降低血小板减少症和溶血的严重程度，稳定狼疮活动，预防围产期出血，并缩短住院时间，但它可能诱发可逆性间质性肾炎和膜性肾小球肾炎。IVIG可能有益于处理与HIT、HELLP综合征和SLE相关的严重围产期孕产妇血小板减少症。
